ONYX 838

Drug Profile

ONYX 838

Latest Information Update: 22 Aug 2002

Price : $50

At a glance

  • Originator Onyx Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 22 Aug 2002 Discontinued - Preclinical for Cancer in USA (unspecified route)
  • 26 Nov 2001 A preclinical study has been added to the Cancer pharmacodynamics section
  • 23 Nov 2001 ONYX 838 is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top